$12.76
2.74% today
Nasdaq, Apr 04, 09:18 pm CET
ISIN
US87410C1045
Symbol
TRML
Sector
Industry

Talaris Therapeutics Inc Stock price

$13.12
+0.79 6.41% 1M
-13.13 50.02% 6M
-7.16 35.31% YTD
-8.78 40.09% 1Y
-30.46 69.89% 3Y
-62.39 82.63% 5Y
-62.39 82.63% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.28 2.09%
ISIN
US87410C1045
Symbol
TRML
Sector
Industry

Key metrics

Market capitalization $336.99m
P/E (TTM) P/E ratio negative
P/B ratio (TTM) P/B ratio 1.05
Dividend yield 0.00%
Last dividend (FY23) $15.12
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-89.73m
Cash position $294.94m
EPS (TTM) EPS $-2.88
P/E forward negative
Short interest 14.89%
Show more

Is Talaris Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Talaris Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Talaris Therapeutics Inc forecast:

10x Buy
100%

Analyst Opinions

10 Analysts have issued a Talaris Therapeutics Inc forecast:

Buy
100%

Financial data from Talaris Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.03 0.03
97% 97%
-
- -
-
-
- Selling and Administrative Expenses 23 23
16% 16%
-
- Research and Development Expense 67 67
160% 160%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -90 -90
66% 66%
-
Net Profit -73 -73
28% 28%
-

In millions USD.

Don't miss a Thing! We will send you all news about Talaris Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Talaris Therapeutics Inc Stock News

Neutral
GlobeNewsWire
22 days ago
– Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease over-enrolled to 143 total participants, on track to report topline data in the second quarter of 2025 – – Cardiovascular Scientific Advisory Board strengthened with recent appointments of Drs. Deepak L. Bhatt, Dipender Gill, Paul M.
Neutral
GlobeNewsWire
about one month ago
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the follow...

Company Profile

Talaris Therapeutics, Inc. engages in cell therapy. It develops methods of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Its technologies are used to treat inherited metabolic enzyme disorders, red blood cell disorders to induce tolerance to organ transplants, and to treat autoimmune disorders such as type 1 diabetes, multiple sclerosis, rheumatoid arthritis, and scleroderma. The company was founded by Suzanne Ildstad in 2002 and is headquartered in Louisville, KY.

Head office United States
CEO Sandeep Kulkarni
Founded 2021
Website www.tourmalinebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today